an Open Access Journal by MDPI

Advanced Research in Early Pregnancy Loss

Guest Editors:

Prof. Dr. Chi Chiu Wang

Sichuan University Joint Laboratory for Reproductive Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong

Prof. Dr. Tao Zhang

Department of Obstetrics & Gynecology, The Chinese University of Hong Kong, Hong Kong, China

Deadline for manuscript submissions:

closed (30 June 2023)

Message from the Guest Editors

Early human pregnancy is a complex procedure involving a of maternal endocrinological, immunological, hematological, cellular and molecular adaptions that are critical to establish a dynamical homeostatic environment for embryo implantation, decidualization, placentation and fetal development. Accumulated evidence has shown that the disruption of this delicately modulated homeostasis will cause implantation failure, insufficient decidualization, and defective placentation. Furthermore, it can occur consecutively, i.e., recurrent implantation failure and miscarriage. Thanks to the rapid development and application of biomedicines, omics and molecular techniques, new and exciting findings have been emerging to unveil the underlying mechanism of pregnancy loss, especially in terms of maternal adaptions and maternalfetal interactions. This Special Issue will focus on the advances and updates in the research of early pregnancy loss, including the underlying mechanisms, from signaling pathways and cellular functions, to animal studies and translational studies with potential clinical applications.

Prof. Dr. Chi Chiu Wang Prof. Dr. Tao Zhang Guest Editors







IMPACT FACTOR 4.7





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us